Thrombospondin-2 as a Biomarker of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
DOI:
https://doi.org/10.24871/2632025263-267Keywords:
Hepatic fibrosis, MAFLD, Trombospondin-2 (TSP-2)Abstract
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is a highly prevalent liver disorder associated with obesity and metabolic syndrome, replacing the term Non-Alcoholic Fatty Liver Disease (NAFLD). The diagnosis of MAFLD is established based on the presence of hepatic steatosis accompanied by metabolic abnormalities such as overweight/obesity, type 2 diabetes mellitus, or metabolic dysregulation. Although liver biopsy remains the gold standard for diagnosis, its invasive nature underscores the need for practical, non-invasive biomarkers. This review aims to summarize the current evidence regarding thrombospondin-2 (TSP-2) as a potential biomarker of hepatic fibrosis in MAFLD. Recent data indicate that serum TSP-2 levels correlate with the severity of steatosis, inflammation, and fibrosis. TSP-2 also shows promise in distinguishing simple steatosis from steatohepatitis and in identifying patients at risk of advanced fibrosis. While these findings highlight the potential role of TSP-2 in diagnosis and disease monitoring, further clinical validation is required before its routine implementation in clinical practice.References
Zheng M-H, Pan J-W, Lu J-Q, et al. A meta-analysis and systematic review of 10 739 607 individuals: overall prevalence of MAFLD was 38.77% (95% CI 32.94-44.95). J Clin Endocrinol Metab. 2024;107(9):2691-2702.
Eslam M, Sarin SK, Wong VWS, et al. Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease (MAFLD). Hepatol Int. 2020;14(6):889-919.
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with NAFLD. Gastroenterology. 2015;149(2):389–97.
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49(3):1017–44.
Mak JHC, Lui DTW, Fong CHY, Cheung CYY, Wong Y, Lee ACH, et al. Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes. Clin Endocrinol (Oxf). 2024;100(3):230–7.
Bornstein P. Thrombospondins: structure and regulation of expression. FASEB J. 1992;6(14):3290–9.
Calabro NE, Kristofik NJ, Kyriakides TR. Thrombospondin-2 and extracellular matrix assembly. Biochim Biophys Acta. 2014;1840(8):2396–402.
Lee CH, Seto WK, Lui DTW, Fong CHY, Wan HY, Cheung CYY, et al. Circulating thrombospondin-2 as a novel fibrosis biomarker of NAFLD in type 2 diabetes. Diabetes Care. 2021;44(9):2089–97.
Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology. 2021;74(5):2452–66.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46.
Xu R, Tao A, Zhang S, Deng Y, Chen G. Roles of NLRP3 inflammasome in liver diseases: focusing on nonalcoholic fatty liver disease. Front Immunol. 2020;11:609924.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83.
Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of metabolic dysfunction-associated fatty liver disease. Nat Rev Gastroenterol Hepatol. 2021;18(6):387–400.
Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397–411.
Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities associated with disordered collagen fibrillogenesis, increased vascular density, and a bleeding diathesis. J Cell Biol. 1998;140(2):419–30.
Zhang N, Wu X, Zhang W, Sun Y, Yan X, Xu A, et al. Targeting thrombospondin-2 retards liver fibrosis by inhibiting TLR4-FAK/TGF-β signaling. JHEP Rep. 2024;6(3):101014.
Chen W, Wu X, Yan X, Xu A, Yang A, You H. Multi-transcriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression. Am J Physiol Gastrointest Liver Physiol. 2019;316(6):G744–54.
Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Non-invasive markers of fibrosis in NAFLD: validating the European Liver Fibrosis panel and exploring simple markers. Hepatology. 2008;47(2):455–60.
Nishikawa H, Enomoto H, Iwata Y, Nishimura T, Kita R, Kimura T, et al. Serum WFA+-M2BP as a diagnostic marker of liver fibrosis in NAFLD. Hepatol Res. 2016;46(10):1042–51.
Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2019;69(3):1075–86.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).